SAN FRANCISCO -- Radiation therapy (RT) after surgery for high-risk muscle-invasive bladder cancer significantly reduced the rate of local recurrence and improved survival, according to a randomized ...

Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...

Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the ...

In a phase 2 study, researchers added pembrolizumab to chemoradiation and surgery for muscle-invasive bladder cancer. 60 ...

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

While the method may sound unfamiliar, it has been clinically validated for decades and remains central to preventing ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...